Nilo Therapeutics has closed a $101 million Series A and named Kim Seth as chief executive officer and board member. The round was led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments. Co-founded by Charles Zuker, Ruslan Medzhitov, and Steve Liberles, Nilo is building a pipeline of drugs designed to restore immune homeostasis by modulating neural circuits. The company will use the proceeds to establish a New York City laboratory, expand its interdisciplinary R&D team, and advance preclinical programs under the scientific leadership of chief scientific officer Laurens Kruidenier.
The financing puts significant weight behind a contrarian thesis in immunology: that the most efficient lever to control inflammatory disease may sit in the brain–body axis rather than at a single immune target. Rather than suppressing downstream cytokines or cell types, Nilo is pursuing pharmacologic modulation of vagal and related circuits that function as master regulators of systemic immune activation. It is a deliberate attempt to capture the promise glimpsed in bioelectronic medicine—where device-based vagus nerve stimulation has shown signals in rheumatoid arthritis and inflammatory bowel disease—and translate it into scalable, drug-like interventions.
For Commercial leaders, the timing matters. Autoimmune markets are crowded with agents offering incremental efficacy at rising cost, while safety debates around JAK inhibitors and long-term immunosuppression continue to pressure access. If central circuit modulation can deliver multi-pathway control without broad immunosuppression, differentiation could extend beyond mechanism to durability, steroid sparing, and reduced healthcare utilization. That claim will require rigorous evidence: biomarker-defined patient subsets, consistent effects across heterogeneous phenotypes, and clear safety readouts that address CNS penetration and neuropsychiatric risk. Payers will demand hard outcomes and real-world data demonstrating reduced flares, fewer hospitalizations, and lower total cost, not just inflammatory biomarker shifts.
Medical Affairs teams should anticipate a steep education curve. Positioning a CNS-acting immunomodulator will require translational narratives that link autonomic tone, cytokine networks, and disease activity, supported by objective measures such as heart rate variability, cytokine signatures, and neuroimaging where relevant. Trial designs that incorporate mechanistic endpoints, early proof-of-mechanism in healthy volunteers or narrow phenotypes, and pragmatic extension studies will be central to shaping clinical practice and payer policy. Post-approval, adherence, monitoring, and safety management will likely look different from conventional biologics, raising new questions about HCP workflows and patient support.
Strategically, this is also a financing signal. In a constrained biotech market, a nine-figure Series A anchored by a top-tier syndicate suggests a willingness to back deep biology platforms that can spawn multiple shots on goal. The presence of the Gates Foundation hints at broader applicability to inflammatory complications in infectious diseases and global health contexts. With its base in New York City, Nilo adds momentum to the city’s growing bench of translational biotech, while Kruidenier’s track record in precision immunology and the acquisition of Prometheus by Merck underscore an enduring pharma appetite for differentiated I&I mechanisms tied to strong biomarker strategies.
The next inflection points are clear: indication selection that showcases the breadth of the mechanism, the modality choice that balances CNS access with safety, and early human proof that circuit-level modulation can recalibrate immunity in a durable, selective manner. If that data materializes, the question for incumbents is not whether to partner but where neuroimmune therapeutics will sit in the treatment sequence—and whether portfolios built around cytokine silos will need to be re-architected around the neural control layer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
